KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (KaloBios) is a private held, biopharmaceutical company that is engaged in the development of new human antibody therapeutics based on its proprietary antibody engineering technology. The humaneering technology of KaloBios is a method for converting non human antibodies into engineered human antibodies. The company is focused on developing and commercializing biotherapies to treat unmet medical needs. The product pipeline of KaloBios, include KB00 for the treatment of pseudomonas aeruginosa infections; KB002 and KB003 for the treatment of inflammatory diseases and KB004 for the treatment of cancer. Recently, the company has partnership with Sanofi Pasteur Ltd for the development and commercialization of a humaneered antibody KB001, to treat and prevent pseudomonas aeruginosa infections. KaloBios is headquartered at South San Francisco in California, the US.